Emergent BioSolutions | EBS - Текущие обязательства





Текущие обязательства Изменить Дата
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Akebia Therapeutics USD 160.86M 13.02M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amarin USD 164.2M 15.45M 2026-06
ANI Pharmaceuticals USD 283.65M 44.14M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Coherus Biosciences USD 75.51M 56.82M 2026-06
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exelixis USD 361.93M 9.05M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Heron Therapeutics USD 92.14M 1.63M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Myriad Genetics USD 130.7M 500K 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Pacira USD 122.01M 13.22M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
United Therapeutics USD 607.8M 8.7M 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12